ProPhase Labs Announces Financial Results for the Year Ended December 31, 2023 and Significant Progress in Its Strategic Initiatives
15. März 2024 08:00 ET
|
ProPhase Labs, Inc.
Nebula Genomics secures major international B2B deal – Additional significant B2B deals in final stages Ahead of schedule, Pharmaloz Manufacturing accelerates capacity expansion – set for rapid...
PROPHASE LABS TO PRESENT 2023 YEAR END FINANCIAL RESULTS ON MARCH 15, 2024
08. März 2024 08:00 ET
|
ProPhase Labs, Inc.
GARDEN CITY, NY, March 08, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ: PRPH), announced today that they will be presenting full year 2023 financial results on a virtual conference call...
ProPhase Labs Announces Significant Progress in BE-Smart Esophageal Cancer Test Development USPTO grants additional broad patents for BE-SMART
20. Februar 2024 08:00 ET
|
ProPhase Labs, Inc.
Garden City, NY, Feb. 20, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a next generation biotech, genomics and diagnostics company, today announced important developments in the...
ProPhase Labs Announces Preliminary Positive Results for Dietary Supplement Equivir
14. Februar 2024 08:00 ET
|
ProPhase Labs, Inc.
Commercialization of Equivir anticipated after second trial is completed in Q2, 2024 Garden City, NY, Feb. 14, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a next generation...
ProPhase Labs Ushers in New Genomics Era with Jason Karkus at the Helm of Nebula Genomics
30. Januar 2024 08:00 ET
|
ProPhase Labs, Inc.
Garden City, NY, Jan. 30, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next generation biotech, genomics, therapeutics and diagnostics company,...
Pharmaloz Manufacturing Accelerates Expansion, Improves Pricing, Boosts Profitability and Secures New Contracts
23. Januar 2024 08:00 ET
|
ProPhase Labs, Inc.
Pharmaloz Wins Two New Contracts in January that are Anticipated to Significantly Increase Lozenge Revenues and ProfitabilityCompany in Late-Stage Discussions with Two Additional Large Global Brands...
ProPhase poised to ramp up growth at Pharmaloz and Nebula Genomics in 2024
04. Januar 2024 08:00 ET
|
ProPhase Labs, Inc.
Company also plans to commercialize its BE-Smart Esophageal Cancer Test in 2024Company announces the hiring of long-time industry veteran Jed Latkin as COO to help build and manage this growth Garden...
ProPhase Labs Announces Financial Results for the Three Months Ended September 30, 2023
09. November 2023 08:00 ET
|
ProPhase Labs, Inc.
Company sees significant momentum in Pharmaloz, Nebula Genomics and ProPhase BioPharma Pharmaloz Manufacturing plans on track to increase capacity from $10 million to over $75 million in 2024...
ProPhase Labs to Host Third Quarter 2023 Financial Results Conference Call on Thursday, November 9, 2023 at 11:00 a.m. Eastern Time
02. November 2023 08:00 ET
|
ProPhase Labs, Inc.
GARDEN CITY, NY, Nov. 02, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a next generation biotech, genomics, therapeutics and diagnostics company, will hold a conference call on...
ProPhase Labs Announces Substantial Growth Expectations for Pharmaloz Manufacturing Subsidiary due to Skyrocketing Demand for Pharmaloz Output.
17. Oktober 2023 08:00 ET
|
ProPhase Labs, Inc.
Pharmaloz plan is to build capacity with a goal to attain a revenue run-rate of $60 to $80 million by year-end 2024, with 20-25% pre-tax net margins and a goal for additional growth thereafter. ...